Ekf Diagnostics Holding PLC’s Buy Rating Reaffirmed at N+1 Singer (EKF)
Ekf Diagnostics Holding PLC (LON:EKF)‘s stock had its “buy” rating restated by N+1 Singer in a research note issued on Wednesday. They currently have a GBX 38 ($0.65) price objective on the stock. N+1 Singer’s price target suggests a potential upside of 44.76% from the stock’s previous close.
A number of other firms have also recently commented on EKF. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of Ekf Diagnostics Holding PLC in a research note on Monday, June 2nd. They now have a GBX 48 ($0.81) price target on the stock. Separately, analysts at FinnCap reiterated a “buy” rating on shares of Ekf Diagnostics Holding PLC in a research note on Monday, June 2nd. They now have a GBX 38 ($0.65) price target on the stock. Finally, analysts at FinnCap initiated coverage on shares of Ekf Diagnostics Holding PLC in a research note on Thursday, May 22nd. They set a “buy” rating and a GBX 38 ($0.65) price target on the stock. Five investment analysts have rated the stock with a buy rating, Ekf Diagnostics Holding PLC has an average rating of “Buy” and an average target price of GBX 40.60 ($0.69).
Shares of Ekf Diagnostics Holding PLC (LON:EKF) traded down 1.46% on Wednesday, hitting GBX 25.375. 18,377 shares of the company’s stock traded hands. Ekf Diagnostics Holding PLC has a one year low of GBX 23.60 and a one year high of GBX 43.00. The stock’s 50-day moving average is GBX 27.13 and its 200-day moving average is GBX 33.10.
EKF Diagnostics Holdings Plc designs, develops, manufactures and sells diagnostic instruments, reagents and certain ancillary products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.